Coherus BioSciences Inc Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to Coherus Ophthalmology franchise divestiture conference call. At this time, all participants are in a listen only mode because the speakers' presentation there will be a question-and-answer session to ask a question. (Operator Instructions)
Please be advised that today's conference is being recorded. I would like now to turn the conference over to Jami Taylor, Head of Investor Relations. Please go ahead.
Thank you, Michelle. Good morning, everyone, and thank you for joining us today. I am Jamie Taylor, Head of Investor Relations at Coherus. Earlier today, we issued a press release announcing the divestiture of our similarly ophthalmology franchise to Sandoz in a $170 million upfront all cash deal.
That announcement is the sole and primary topic of this call with us today to offer insight into this news is Denny Lanfear, Chairman and Chief Executive Officer of Coherus. Available during the Q&A portion of our call today are Bryan
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |